Quarry LP Sells 551 Shares of DexCom, Inc. (NASDAQ:DXCM)

Quarry LP lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 67.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265 shares of the medical device company’s stock after selling 551 shares during the period. Quarry LP’s holdings in DexCom were worth $33,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Capital World Investors grew its position in DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Norges Bank purchased a new position in shares of DexCom in the 4th quarter worth about $540,178,000. Artisan Partners Limited Partnership boosted its holdings in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Capital Research Global Investors increased its position in shares of DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of DexCom during the 4th quarter valued at about $231,773,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $116.53 on Tuesday. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The stock’s 50 day simple moving average is $127.10 and its two-hundred day simple moving average is $125.99. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a market cap of $46.34 billion, a price-to-earnings ratio of 75.18, a PEG ratio of 2.83 and a beta of 1.22.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $140.94.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the sale, the chief executive officer now directly owns 283,893 shares in the company, valued at $39,262,401.90. The disclosure for this sale can be found here. Insiders have sold 60,837 shares of company stock valued at $8,377,125 in the last three months. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.